UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $4 Million Holdings in Sarepta Therapeutics, Inc. $SRPT

Key Points

• UBS Asset Management reduced its Sarepta Therapeutics stake by 19.7% in the second quarter, selling 54,459 shares and retaining 222,496 shares worth approximately $4 million.
• Institutional investors own 86.68% of Sarepta, with BlackRock acquiring a new stake worth about $341.3 million and AQR Capital increasing its holdings by 454.6%.
• Sarepta beat quarterly earnings and revenue expectations, but revenue fell 34.3% year over year. Analysts have an overall “Hold” rating, with an average price target of $25.69 versus the stock’s reported $22.02 price.

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC cut its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 19.7% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 222,496 shares of the biotechnology company's stock after selling 54,459 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.21% of Sarepta Therapeutics worth $3,998,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of SRPT. BlackRock Inc. acquired a new stake in shares of Sarepta Therapeutics in the second quarter worth about $341,339,000. AQR Capital Management LLC raised its stake in shares of Sarepta Therapeutics by 454.6% in the 4th quarter. AQR Capital Management LLC now owns 7,796,535 shares of the biotechnology company's stock valued at $167,781,000 after acquiring an additional 6,390,860 shares in the last quarter. First Trust Advisors LP lifted its holdings in Sarepta Therapeutics by 107.6% in the 1st quarter. First Trust Advisors LP now owns 4,135,788 shares of the biotechnology company's stock worth $89,995,000 after purchasing an additional 2,143,211 shares during the last quarter. Erste Asset Management GmbH lifted its holdings in Sarepta Therapeutics by 1.6% in the 4th quarter. Erste Asset Management GmbH now owns 2,728,945 shares of the biotechnology company's stock worth $58,727,000 after purchasing an additional 43,000 shares during the last quarter. Finally, Bank of America Corp DE lifted its holdings in Sarepta Therapeutics by 26.6% in the 1st quarter. Bank of America Corp DE now owns 2,145,926 shares of the biotechnology company's stock worth $46,695,000 after purchasing an additional 450,336 shares during the last quarter. 86.68% of the stock is currently owned by institutional investors.

Sarepta Therapeutics Stock Performance

SRPT opened at $22.02 on Thursday. The firm has a market capitalization of $2.33 billion, a P/E ratio of -7.59, a price-to-earnings-growth ratio of 0.30 and a beta of 0.27. The stock's 50 day moving average price is $18.50 and its two-hundred day moving average price is $18.55. The company has a quick ratio of 2.62, a current ratio of 4.42 and a debt-to-equity ratio of 0.55. Sarepta Therapeutics, Inc. has a 12-month low of $14.68 and a 12-month high of $25.32.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.64 EPS for the quarter, topping analysts' consensus estimates of $0.22 by $0.42. Sarepta Therapeutics had a negative return on equity of 1.60% and a negative net margin of 13.48%.The company had revenue of $401.25 million during the quarter, compared to analyst estimates of $366.39 million. During the same period in the previous year, the company earned $2.02 earnings per share. The company's quarterly revenue was down 34.3% compared to the same quarter last year. On average, equities analysts forecast that Sarepta Therapeutics, Inc. will post 3.52 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have commented on the company. Benchmark reiterated a "sell" rating on shares of Sarepta Therapeutics in a report on Wednesday. Wall Street Zen downgraded shares of Sarepta Therapeutics from a "buy" rating to a "hold" rating in a report on Saturday, August 8th. Piper Sandler decreased their price objective on shares of Sarepta Therapeutics from $23.00 to $20.00 and set a "neutral" rating for the company in a report on Thursday, July 9th. Wolfe Research upgraded shares of Sarepta Therapeutics from a "peer perform" rating to an "outperform" rating and set a $27.00 target price on the stock in a research note on Thursday, July 9th. Finally, Weiss Ratings upgraded shares of Sarepta Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a report on Tuesday. Nine analysts have rated the stock with a Buy rating, five have assigned a Hold rating and six have given a Sell rating to the company. According to MarketBeat.com, Sarepta Therapeutics presently has an average rating of "Hold" and an average target price of $25.69.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta's core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company's mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta's commercial products include several exon-skipping therapies approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.